Stocks and Investing
Stocks and Investing
Tue, June 27, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Michael Schmidt Downgraded (ACET) to Hold and Held Target at $20 on, Jun 27th, 2023
Michael Schmidt of Guggenheim, Downgraded "Adicet Bio, Inc." (ACET) to Hold and Held Target at $20 on, Jun 27th, 2023.
Michael has made no other calls on ACET in the last 4 months.
There are 2 other peers that have a rating on ACET. Out of the 2 peers that are also analyzing ACET, 1 agrees with Michael's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Brian Cheng of "JP Morgan" Downgraded from Buy to Hold and Decreased Target to $6 on, Thursday, June 1st, 2023
This is the rating of the analyst that currently disagrees with Michael
- Robert Driscoll of "Wedbush" Reiterated at Buy and Held Target at $30 on, Wednesday, May 10th, 2023
Contributing Sources